Trump unveils phased generic drug tariffs
Washington, July 22
US President Donald Trump has announced that imported generic medicines will remain free of tariffs for two years from August 1, 2026, before facing duties of 100 per cent and later 200 per cent as part of his push to shift pharmaceutical production to the United States.
The announcement gives overseas generic drug manufacturers a two-year window to establish production facilities in the US or face steep tariffs on medicines shipped to the American market.
"Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which the TARIFF will be raised to 100% for a one year period of time, and 200% thereafter," Trump said in a social media post on Tuesday.
The policy could carry major implications for global pharmaceutical manufacturers that supply generic medicines to the US. Trump's statement did not name any country or company and offered no details about how the tariff system would be administered.
It also did not specify whether companies that begin building plants during the two-year period would qualify for an exemption or whether production would have to start before the higher duties take effect.
Trump said the phased tariff structure was intended to encourage drugmakers to invest in American manufacturing facilities.
"This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them," he said.
"The objective of this Policy is to protect the people of the United States," Trump added.
Under the timeline announced by the president, generic drug imports would continue to enter the US without tariffs for two years after August 1. They would then face a 100 per cent tariff for one year, followed by a 200 per cent duty.
Trump distinguished the new timetable for generic medicines from his administration's treatment of patented and branded drugs.
"The Policy on Patented, Branded, or Innovative Drugs, which has been so successful, will remain as is," he said, without providing further details about that policy in the announcement.
The president said pharmaceutical companies were already expanding their manufacturing presence across the country.
"Pharmaceutical Facilities are being built, at a level never seen before, all over the United States of America," Trump said.
— IANS
Reader Comments
Typical America First policy. But let's be real - Indian companies like Sun Pharma and Dr Reddy's have the margins to set up US plants if they want. The real issue is the uncertainty. What if Trump is not in power after 2028? All that investment could become useless. Our pharma industry needs to diversify exports to Europe and Asia instead of depending so much on the US.
Honestly, I don't blame Trump. If India can put tariffs on American goods, why can't America do the same? We have to accept that global trade is becoming more nationalistic. Our pharma companies have been making huge profits from the US market for decades. Time to adapt or lose out. But 200% tariff is insane though 😅
This will increase medicine prices in America, but it's their problem. More concerning for us is the potential job losses in Hyderabad and Ahmedabad pharma hubs. The government should announce a package for these workers if things go south. Also, why is there no equivalent push in India to manufacture our own APIs? We import so much from China.
This is bad news for affordable healthcare worldwide. Indian generics kept US drug prices low for years. Now Trump wants to destroy that. But let's also be honest - our companies have been cutting corners on quality sometimes. Maybe this forced localization will make everyone more competitive. Still, a 200% tariff is basically a ban.
I work in pharma exports and this is scary. But we saw it coming. Remember when Trump first started
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.